Apo(a) phenotyping and long-term prognosis for coronary artery disease.: Apo(a) phenotype and coronary artery disease.
Introduction
Lipoprotein (a) [Lp(a)] is a complex lipoprotein particle in human plasma.
It is composed of apolipoprotein B (apoB100) and apolipoprotein (a) [apo(a)] which are linked by a disulfide bond. Apo(a) consists of a serine proteinase region and several kringle domains, derived from those of plasminogen but presenting some distinctive features. 1 Only plasminogen's kringle 5 (one copy) and 4 (multiple copies) are present in apo(a). The copies of apo(a) kringle 4 are not alike: 10 different types have been recognized. 2 Each type is present only once, except for kringle 4, type 2, which is present in multiple copies. This variation in copy number of kringle 4, type 2 domains results in structural heterogeneity of Lp(a) and isoforms whose molecular weights range from 280 to 800 kDa. Smaller isoforms of apo(a) with correspondingly fewer kringle 4, type 2 domains correlate inversely with Lp(a) plasma concentration. 3 Plasma levels of Lp(a) vary greatly among individuals. Elevated plasma levels of Lp(a) have been shown to be an independent risk factor for coronary artery diseases (CAD). The level of Lp(a) is controlled by a single gene with multiple alleles; each allele affects the concentration of Lp(a) 4 .differently. The interindividual variation in plasma concentrations is almost entirely controlled by the apo(a) locus on chromosome 6q26-q27 and can be explained by a variable number of transcribed kringle4 repeats (KIV-VNTR).
External environmental factors have little impact on the pathogenicity of plasma Lp(a); however internal environmental characteristics such as the ability to undergo oxidation or the action of proteolytic or lipolytic enzymes can modify Lp(a)'s pathogenicity. Transient circumstances such as inflammation can also cause increases in plasma concentration and result in the apo-(a) being partially divided by polymorphonuclear neutrophils (PMNs) elastase, forming lower molecular weight structures 5 . It is important to stress this fact because when low molecular weight isoforms of apo(a) are present in the Lp(a) molecule, Lp(a) exhibits a greater affinity for fibrin and competitively inhibits plasminogen binding, thus generating a fibrinolytic shortfall 6 . Surprisingly, isolated apo(a) (10 to 34 kringles) has been shown to display a high affinity for fibrin 7 , independent of its size.
The pathological routes by which Lp(a) can lead to an atheroscleroticprone condition or by which a procoagulant mechanism is created by Lp(a) in the atherosclerotic plaque have been explored previously. Proposed mechanisms include the inhibition of the conversion of Glu-plasminogen to Lysplasminogen 8 , the alteration of the secretion of tissue-type plasminogen activator, the prolongation of fibrinolysis time due to the thinning of fibrin fibers 9 , an increase in binding to tissue factor pathway inhibitor (TFPI) 10 , and an increase in platelet aggregation through the interaction of apo(a) with a specific receptor at the platelet surface 11 which induces endothelial dysfunction [12] [13] . In transgenic mice, Lp(a) has been shown to increase the concentration of cholesterol-rich remnant lipoproteins and the atherosclerosis lesion area in the aortic root 14 . Moreover, Lp(a) shows a synergistic effect with homocysteine 15 another atherogenic particle.
It is also important to note that apo(a) has properties independent of Lp(a). For example, oxidized proinflammatory phospholipids in apoB-100 particles are preferentially sequestered on Lp(a), 16 which induces avid uptake by monocyte-macrophages recruits 17 . Another very interesting study shows evidence that the origin of oxidized phospholipids in Lp(a) is apo(a) rather than LDL, independent of plasma concentration or the isoform of apo(a) 18 . It has been shown that vascular endothelial cell growth, migration, contraction and cell permeability 19 , 20 are all induced by apo(a).
The evidence suggests that there is no single pathophysiological mechanism leading to the development of CAD and induced by Lp In the present work we analyze the impact of apo(a) on the course of cardiovascular and cerebrovascular diseases in a population using a functional approach (the binding of apo(a) and fibrin), Lp(a) plasma concentration, and apo(a) phenotyping determined about eight years previously. Death, non-fatal myocardial infarction, unstable angina, need for myocardial revascularization (percutaneous or surgical), and ischemic stroke were monitored over 8 years of follow-up.
Methods
We included patients born in Mexico who had a history of CAD defined as myocardial infarction and/or unstable angina (> 3 months) or stable angina and who had been followed up at the outpatient clinic of the National Institute of Cardiology "Ignacio Chavez". From January 1997 to December 1999, we conducted a case controlled study with the aim of evaluating the impact of Lp(a) in CAD and cerebrovascular disease. Sixty-eight patients with CAD were monitored and included in this analysis.
Patients were considered positive for type 2 diabetes mellitus if they were receiving hypoglycemic and/or insulin treatment or if fasting glucose levels were 126 mg/dL on 2 or more occasions. Patients were classified as having systemic hypertension with a prior diagnosis or with established antihypertensive treatment. Dyslipidemic patients had hypercholesterolemia (as determined by prior diagnosis, total cholesterol levels equal to or greater than 240 mg/dL, LDL cholesterol levels equal to or greater than 160 mg/dL or HDL cholesterol levels lower than 40 mg/dL) and/or hypertriglyceridemia (as determined by prior diagnosis, treatment with fibrates or serum triglycerides equal to or greater than 150 mg/dL). Patients were classified as prior smokers if they had a history of smoking 5 or more cigarettes a day and had abstained for longer than a year.
Patients were considered active smokers if they smoked 5 or more cigarettes a day at the beginning of the study or had abstained for less than a year. All patients were treated with aspirin, statins, beta blockers and angiotensinconverting enzyme inhibitors (ACE-i).
The extent of CAD was estimated by determining the percentage of internal luminal narrowing. Involvement of one vessel was considered hemodynamically significant with more than a 50% reduction in the diameter of an important vessel (left anterior descending, circumflex or right coronary).
Involvement of 2 vessels meant significant stenosis in two coronary vessels or a narrowing of 50% or more in the left main trunk, and involvement of 3 vessels meant significant stenosis in three coronary vessels.
As previously reported 33 
Statistics
We used descriptive statistics with median ± SD and median with minimum and maximum values in accordance with their distribution. The Kolmogorov-Smirnov test was used as evidence of normality. The student t test or the Mann-Whitney U test was used to compare continuous variables between groups. Categorical variables were reported as absolute values or percentages and compared with a chi-square test or Fisher exact test for frequencies lower than 5. Lp(a) concentration, binding and apo(a) size, as well as age, gender, traditional risk factors, three-vessel disease, and left ventricle systolic dysfunction were included in a logistic regression model. Apo(a) size was dichotomized for analysis at the 22K isoform. Low molecular weight apo(a) isoforms were designated by convention as ≤22K-IV repeats 29 .
The primary end point of the study was the incidence of MACCE at follow-up. The primary end point was defined to be the event which occurred first. Events were counted only once,. We used tables of Kaplan-Meier survival to evaluate the primary endpoint as either death, non-fatal myocardial infarction, need for revascularization (percutaneous or surgical) or ischemic stroke. We censored cases that were losses in monitoring (patients lost to follow-up were considered at risk until the date of last contact, at which point they were removed from consideration). Comparison between groups was carried out using the logrank test (Log Rank). All tests were 2-tails. Differences were considered significant if p <0.05. All analyses were performed with SPSS (version 13.0).
Results
Clinical and demographic characteristics of patients are presented in Table 1 . Prevalent risk factors in both groups were hypertension, dyslipidemia and smoking. At baseline, no differences were observed for age, sex, cardiovascular risk factors, profile of lipids, and medical treatment between both groups. The majority of patients were undergoing pharmacological treatment including aspirin, betablockers and ACEi. A few patients were taking statins and calcium channels blockers at baseline. There was a statistically significant difference in Lp(a) concentration in patients with small apo(a) isoforms compared with large apo(a) isoforms (p=0.02). Interestingly, there were no differences in apo(a) fibrin binding in the groups.
In the multivariate analysis (Table 2) , apo(a) KIV≤22 was an independent risk factor for cardiovascular and cerebrovascular events in patients with CAD (odds ratio (OR) of 4.4, CI of 1.24-15.62, p= 0.021). Apo(a) binding and Lp(a) >30 mg/dL did show a tendency for an increased risk of MACCE, although without the statistical significance seen for apo(a) K-IV≤22.
MACCE in the follow up.
Clinical follow-up was achieved in patients after an average of 6.9 years ± 3.04. There were 3 deaths in the small kringles group (10%) and no deaths in the large kringles group (p = 0.081). MACCE-free survival at follow-up was 27% in patients with apo(a) KIV≤22 and 48% in patients with the larger apo(a) KIV>22 isoform (P=0.051). Incidence of MACCE at follow-up was significantly lower in patients who had the large isoform compared to patients with the small isoform ( Table 3) .
Discussion
The evidence presented here shows that the best approach to evaluate the cardiovascular risk associated with Lp(a) is to determine the isoforms of circulating apo(a). 30 When just measuring plasma concentration of Lp(a), it is not always possible to find such an association 31. Nevertheless, Kamstrup et al, in a recent meta-analysis of 36 prospective studies, found a modest association of elevated Lp(a) concentration with coronary heart disease and stroke 32 .
We previosly reported 33 experimental evidence to support the hypothesis that smaller-sized isoforms of apo(a) increased the potential antifibrinolytic effect in ischemic cardiopathy and cerebrovascular disease. This effect was more evident in the cerebrovascular group, suggesting the existence of peculiar and poorly understood differences in antithrombotic mechanisms in the cerebral and coronary arteries of these patients.
In this study, we found an increase in MACCE even when follow-up was only two years after initial contact in the apo(a) KIV≤22 group, demonstrating that, in a hospital-based population, small apo(a) isoforms are associated with the development of major adverse cardiovascular and cerebrovascular events.
These data agree with other studies that found an association between Lp(a) levels and stroke and death from vascular disease in the elderly. 34 When we examined the relationship between apo(a) fibrin binding and MACCE, we did find an association, although it was not significant according to the multivariate statistical analysis. It is possible that mechanisms other than apo(a) fibrin binding could influence the thrombogenicity of apo(a) and the risk of adverse cardiovascular events. Apo(a) has the ability to preferentially bind proinflammatory oxidized phospholipidl (OxPL) 35 , and it has been shown that there is an association between OxPL and small apo(a) isoforms despite differences in Lp(a) levels. This study does have limitations, including the fact that the analysis was retrospective and the fact that we did not include in the analysis the response of patients to different treatments. However, we believe that when the results presented here are carefully considered, we can conclude that there is a mild mortality risk associated with apo(a) K-IV≤22 in Mexican patients with coronary artery disease. This association may prove clinically useful in risk stratification, helping identify patients with an increased risk of major adverse cardiovascular and cerebrovascular events in the long term. Lp(a)= lipoprotein(a); apo(a)= apolipoprotein(a); MI= myocardial infarction;
LVEF= left ventricular ejection fraction; OR = odds ratio; CI= confidence intervals Freedom from major adverse cardiovascular and cerebrovascular events (death, myocardial infarction, unstable angina, myocardial revascularization , and stroke) at 10 years.
